Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00444314
Recruitment Status : Completed
First Posted : March 7, 2007
Last Update Posted : August 4, 2011
Information provided by:
CASI Pharmaceuticals, Inc.